The Level of Cholesterol in COPD Patients with Severe and Very Severe Stage of the Disease
DOI:
https://doi.org/10.3889/oamjms.2016.063Keywords:
severe and very severe COPD, comorbidity, the level of cholesterol, the level of LDL, the level of HDLAbstract
BACKGROUND: High blood cholesterol is part of metabolic syndrome and can be caused by medical conditions or bad dietary habits.
AIM: The aim of the study was to investigate the prevalence of hypercholesterolemia in privies diagnosed patients with the severe and very severe stage of COPD, which were stable.
MATERIAL AND METHODS: We investigated 100 subjects, all of them smokers, with smoking status >10 years, stratified into two groups: with severe and very severe stage of the disease. It was clinical, randomized, cross-sectional study. Besides demographic parameters and functional parameters, body mass index, cholesterol, LDL, and HDL were investigated.
RESULTS: In the group of patients with very severe COPD were recorded significantly higher average values of cholesterol (6.16 ± 1.5 vs. 5.61 ± 1.1, p = 0.039). As independent significant factors influencing cholesterol in the group with a very severe COPD were confirmed the age of the patients (p = 0.005), LDL (p = 0.004) and HDL (p = 0.002). In the group with severe COPD, only LDL was confirmed as an independent significant factor that has an impact on cholesterol (p < 0.0001).
CONCLUSION: The results of our survey demonstrated a high level of blood cholesterol and LDL, and low level of blood HDL in both investigated group’s patients with COPD.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Barnes P. Chronic Obstructive Pulmonary Disease. N Engl J Med. 2000; 343:269-280. http://dx.doi.org/10.1056/NEJM200007273430407 PMid:10911010
Barnes P. Inflammation in COPD. The Clinical Respiratory Journal. 2011; 5:1–10. http://dx.doi.org/10.1111/j.1752-699X.2011.00265_1.x
Mannino M, Buist S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370:765–773. http://dx.doi.org/10.1016/S0140-6736(07)61380-4
McDonough E, Yuan R, Suzuki M, Seyednejad N, Elliott M, Sanchez G, Wright C, Gefter B, Litzky L, Coxson O. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567–1575. http://dx.doi.org/10.1056/NEJMoa1106955 PMid:22029978 PMCid:PMC3238466
Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. [Last accessed on 2013 Feb 15]. www.goldcopd.org
Ulubafl B, Çimen F, Erylmaz T,Budayc R, Çalkolu M. Lipid Profile in Patients with Chronic Obstructive Pulmonary Disease. Respiratory Journal. 2003;4:(3):120-122
Jung U, Choi M. Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2014;15(4): 6184–6223. http://dx.doi.org/10.3390/ijms15046184 PMid:24733068 PMCid:PMC4013623
Suzuki M, Makita H, Ito M. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J. 2014;43:1289–1297. http://dx.doi.org/10.1183/09031936.00110213 PMid:24232696
Nishimura M, Makita H, Nagai K. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:44–52. http://dx.doi.org/10.1164/rccm.201106-0992OC PMid:22016444
Watz H, Waschki B, Kirsten A, Müller C, Kretschmar G, Meyer T, Holz O, Magnussen H. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009;136(4):1039-46. http://dx.doi.org/10.1378/chest.09-0393 PMid:19542257
Akpınar E, Akpınar S, Ertek S, Sayın E, Gülhan M. Systemic inflammation and metabolic syndrome in stable COPD patients. Atherosclerosis. 1999;147(2):249-52.
Waseem S, Hossain M, Rizvi A, Ahmad Z, Islam N. Oxidative Stress and Lipid Profile in COPD Patients: Beneficial Role of Exercise and Scope for Improvement. Biomedical Research. 2013;24 (1):135-138.
Jurczak I, Jurczak K. Chronic obstructive pulmonary disease as a risk factor for coronary heart disease. Pol Merkur Lekarski. 2015;38(223):39-41.
Boschetto P, Beghé B, Fabbri L, Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology. 2012;17(3):422-31. http://dx.doi.org/10.1111/j.1440-1843.2011.02118.x PMid:22142519
Young R, Hopkins R. Role of Statins in Chronic Obstructive Pulmonary Disease and its Co-morbidities. Expert Rev Resp Med. 2013;7(5):533-544. http://dx.doi.org/10.1586/17476348.2013.838018 PMid:24138695
Mroz R, Lisowski P, Tycinska A, Bierla J, Trzeciak P, Minarowski L, Milewski R, Lisowska A, Boros P, Sobkowicz B, Duszewska A, Chyczewska E, Musial W, MacNee W. Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. Physiol Pharmacol. 2015;66(1):111-28.
Küpeli E, Ulubay G, Ulasli S, Sahin T, Erayman Z, Gürsoy A. Metabolic Syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocr Jour. 2010;38(1):76-82. http://dx.doi.org/10.1007/s12020-010-9351-3 PMid:20960105
Reed R, Iacono A, DeFilippis A, Eberlein M, Girgis R, Jones S. Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. Heart Lung Transplant. 2011;30(6):674-8. http://dx.doi.org/10.1016/j.healun.2010.12.010 PMid:21306919
Breyer M, Spruit M, Hanson C, Franssen F, Vanfleteren L, Groenen M. Prevalence of Metabolic Syndrome in COPD Patients and Its Consequences. PLoS ONE. 2014;9(6):e98013. http://dx.doi.org/10.1371/journal.pone.0098013 PMid:24950070 PMCid:PMC4064974
Sin D, Man S. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514-9. http://dx.doi.org/10.1161/01.CIR.0000056767.69054.B3 PMid:12654609
Sidney S, Sore M, Charles P. Quesenberry J, DeLuise C, Lanes S, Eisner M. COPD and Incident Cardiovascular Disease Hospitalizations and Mortality. Chest. 2005;128(4):2068-2075. http://dx.doi.org/10.1378/chest.128.4.2068 PMid:16236856
Reed R, Wise R, Dobs A, Lechtzin N, Girgis R. Respir Med. Elevated HDL cholesterol levels are associated with osteoporosis in lung transplant candidates with chronic obstructive pulmonary disease. Respir Med. 2010;104(12):1943-50. http://dx.doi.org/10.1016/j.rmed.2010.08.004 PMid:20801628
Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó J. Chronic obstructive pulmonary disease. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort tudy. Thorax. 2006; 61:772-778. http://dx.doi.org/10.1136/thx.2006.060145 PMid:16738033 PMCid:PMC2117100
Tisi G, Conriquea A, Barrett-Connora E, Grundya S. Increased high density lipoprotein cholesterol in obstructive pulmonary disease (predominant emphysematous type). Metabolisam. 1981;30(4): 340–346. http://dx.doi.org/10.1016/0026-0495(81)90113-X
Reed R, Iacono A, DeFilippis A, Eberlein M, Girgis R, Steven Jones S. Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J of Heart and Lung Transpla. 2011;30(6):674–678. http://dx.doi.org/10.1016/j.healun.2010.12.010 PMid:21306919
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
